Oncology Pharma Inc.

ONPH

US68235J2015

Pharmaceuticals

Delayed OTC Markets Other stock markets 09:00:50 15/05/2024 pm IST			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		+9,900.00%	-50.00%

2021	NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	CI
2021	Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	CI

Oncology Pharma Inc. Appoints Stefan Gruenwald as an Advisor on its Advisory Board

July 15, 2019 at 05:00 pm IST

Oncology Pharma Inc. announced the appointment of Stefan Gruenwald to its Advisory Board. Dr. S. Gruenwald brings more than 30 years of experience and vast knowledge in both the clinical, scientific and business fields to the company. Dr. Gruenwald has had an impressive career as the former VP of R&D at Becton Dickenson, the former CSO at Pharmingen and the former President at Orbigen. He is currently a co founder and president of Diagnomics.

Latest news about Oncology Pharma Inc.

NanoSmart Pharmaceuticals, Inc. announced that it has received funding from Oncology Pharma Inc.	31/21/31	CI
Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy	10/21/10	CI
Oncology Pharma Inc. Moves to Fund Lead Drug Formulation & IND-Enabling Studies	04/21/04	CI
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent	26/21/26	CI
Oncology Pharma Extends Licensing Agreement with Nanosmart Pharmaceuticals, Inc. for Veterinary Oncology	22/21/22	CI
Oncology Pharma Inc. Announces Henry Smith as New Chairman to Its Scientific Advisory Board	16/21/16	CI
Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for Its Connect2med Clinical Trials Platform	09/21/09	CI
Oncology Pharma Announces the Appointment of James Smith as New Chief Financial Officer	29/21/29	CI
Oncology Pharma Inc. cancelled the acquisition of acquire 50% stake in Diagnomics, Inc.	11/20/11	CI
Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating Covid-19	06/20/06	CI
Oncology Pharma Inc. announced that it expects to receive $38.4 million in funding from SCP Partners	20/19/20	CI
Oncology Pharma Inc. signed a Letter of Intent to acquire 50% stake in Diagnomics, Inc.	11/19/11	CI
Oncology Pharma, Inc. Appoints Dr. Vijay Mahant as the Chief Scientific Officer and Chief Operating Officer	15/19/15	CI
Oncology Pharma Elects Stefan Gruenwald to Its Board of Directors	08/19/08	CI
Oncology Pharma Inc. Appoints Stefan Gruenwald as an Advisor on its Advisory Board	15/19/15	CI
SourcingLink.net, Inc. has Changed its Name to Oncology Pharma Inc	13/19/13	CI
SourcingLink.net Inc. Signs a Letter of Intent with NanoSmart Pharmaceuticals, Inc. for a Licensee and Co-Development Collaboration of NanoSmart's Proprietary Targeted Drug Delivery System for Cancer Drugs	27/19/27	CI
SourcingLink.net to Leverage Pharmacogenomics in Oncology Therapy Development and Clinical Trial Program	05/19/05	CI
SourcingLink.net Inc. cancelled the acquisition of 11 additional lithium claims located on CYR south property in Quebec Canada.	10/18/10	CI
SourcingLink.net Inc. Provides Update on the Lac Fire Lithium Property and Completion of 43-101 Compliant Report with Recommended Work Program	29/18/29	CI
SourcingLink.net Inc. Announces Completion of Phase I Surface Exploration on the Lac Fire Lithium Property in James Bay, Quebec	25/18/25	CI
SourcingLink.net, Inc. to Purchase 11 Lithium Claims Located on the CYR South Property in Quebec, Canada	10/17/10	CI
SourcingLink.net Inc. agreed to acquire 11 additional lithium claims located on CYR south property in Quebec Canada.	10/17/10	CI
SourcingLink.net Inc. Provides an Information Update on the Lac Fire Lithium Property	29/16/29	CI
SourcingLink.net Acquires 8 New Lithium-Tantalum Claims in James Bay, Quebec, Canada	01/16/01	CI

Chart Oncology Pharma Inc.

Duration

Period

More charts

Company Profile

Oncology Pharma, Inc. is an oncology company. The Company is focused on licensing, developing, manufacturing and commercializing therapeutics. The Companyâs research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The Company offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Companyâs NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ONCOLOGY PHARMA INC.	-50.00%	3.87T
ELI LILLY AND COMPANY	+32.66%	71TCr
NOVO NORDISK A/S	+30.77%	60TCr
JOHNSON & JOHNSON	-1.61%	37TCr
MERCK & CO., INC.	+20.28%	33TCr
ABBVIE INC.	+6.20%	29TCr
ASTRAZENECA PLC	+14.77%	24TCr
NOVARTIS AG	+9.13%	21TCr
ROCHE HOLDING AG	-3.97%	20TCr
AMGEN INC.	+9.37%	17TCr

Other Pharmaceuticals